SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

That would be a very simple answer -

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BlackDoggie Member Profile
 
Followed By 7
Posts 422
Boards Moderated 0
Alias Born 02/17/17
160x600 placeholder
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 11/16/2017 4:12:12 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/8/2017 4:34:16 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/8/2017 4:34:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/2/2017 4:33:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/13/2017 7:20:39 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/11/2017 7:53:23 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 7:46:31 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 10/10/2017 9:05:18 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/5/2017 2:56:11 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 10/2/2017 10:00:24 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 9/20/2017 5:10:21 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/8/2017 7:49:58 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/8/2017 7:45:54 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/6/2017 7:01:46 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/25/2017 7:32:05 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/21/2017 4:06:51 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/9/2017 4:05:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/31/2017 5:41:30 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/31/2017 5:04:43 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/28/2017 4:09:10 PM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 7/27/2017 5:24:15 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 7/24/2017 7:42:19 AM
Annual Report (10-k) "Edgar (US Regulatory)" - 7/20/2017 6:05:42 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/14/2017 4:09:06 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) "Edgar (US Regulatory)" - 7/10/2017 5:29:50 PM
BlackDoggie   Friday, 11/10/17 08:04:25 PM
Re: Inoviorulez post# 18109
Post # of 18299 
That would be a very simple answer - if the data was available, that is. There is zero indication that any data on primary endpoints was available, since it's a double-blind trial and it had not been unblinded at that point. In fact, one of the big concessions from the FDA was that CYDY could unblind data on the first 40 and conduct interim endpoint analysis.

Plain and simple, the FDA didn't have the primary endpoint data on 10/12. Unless we're all being blatantly and openly lied to by both the company and the FDA. If you want to argue that they were suggesting that the open label portion of the trial (24 weeks in conjunction with optimized background HAART) is what the FDA was looking at, I can accept that as plausible and still disagree with you.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist